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S U M M A R Y
Objectives: Most data regarding the prognosis in neonatal tetanus originate from regions where limited
resources have historically impeded management. It is not known whether recent improvements in
critical care facilities in many low- and middle-income countries have affected indicators of a poor
prognosis in neonatal tetanus. We aimed to determine the factors associated with worse outcomes in a
Vietnamese hospital with neonatal intensive care facilities.
Methods: Data were collected from 107 cases of neonatal tetanus. Clinical features on admission were
analyzed against mortality and a combined endpoint of ‘death or prolonged hospital stay’.
Results: Multivariable analysis showed that only younger age (odds ratio (OR) for mortality 0.69, 95%
conﬁdence interval (CI) 0.48–0.98) and lower weight (OR for mortality 0.06, 95% CI 0.01–0.54) were
signiﬁcantly associated with both the combined endpoint and death. A shorter period of onset (OR 0.94,
95% CI 0.88–0.99), raised white cell count (OR 1.17, 95% CI 1.02–1.35), and time between ﬁrst symptom
and admission (OR 3.77, 95% CI 1.14–12.51) were also indicators of mortality.
Conclusions: Risk factors for a poor outcome in neonatal tetanus in a setting with critical care facilities
include younger age, lower weight, delay in admission, and leukocytosis.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
The worldwide incidence of neonatal tetanus has reduced
signiﬁcantly following a sustained initiative by the World Health
Organization (WHO) and its partners The United Nations
Children’s Fund (UNICEF) and The United Nations Population
Fund (UNFPA). Latest ﬁgures (June 2014) show only 24 countries
out of 59 originally targeted have still to eliminate the disease.1 The
initiative attempts to eliminate maternal and neonatal tetanus
through improvements in maternal vaccination programmes,
delivery practices, and surveillance systems. In some ‘high-risk’* Corresponding author. Tel.: +84 8 3923 7954; fax: +84 8 9238 904.
E-mail address: lthwaites@oucru.org (C.L. Thwaites).
http://dx.doi.org/10.1016/j.ijid.2014.12.011
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
(http://creativecommons.org/licenses/by/3.0/).areas, supplementary immunization programmes targeting all
women of child-bearing age have been employed.2
Despite these advances, the disease continues to occur.
Elimination of neonatal tetanus is deﬁned as ‘less than one case
per thousand live-births in every district of a country’.3 However,
this does not mean complete eradication, as the causative agent of
tetanus, Clostridium tetani, is ubiquitous in the environment
throughout the world and is able to cause disease in any vulnerable
individual (i.e., neonate with unvaccinated mother).
Maintaining a country’s neonatal tetanus elimination status
requires continued efforts and further resources to strengthen
vaccination programmes, reproductive health services, and surveil-
lance systems. These can be threatened by war or natural disasters.
Tetanus clusters have been reported following tsunamis and
earthquakes in Indonesia, Kashmir, and Haiti.4 It is still not clear
how maternal HIV and malaria affect transplacental protectiveciety for Infectious Diseases. This is an open access article under the CC BY license
Table 1
Clinical and laboratory features of participants on admission (n = 107)
Features n Median (IQR)
Age, days 107 8.0 (6.0–11.0)
Time from ﬁrst symptom to admission, days 104 3.0 (2.0–3.3)
Incubation period, days 105 6.0 (5.0–8.0)
Period of onset, h 102 24.0 (24.0–24.0)
Weight, kg 103 2.8 (2.5–3.0)
Temperature, 8C 84 38.0 (38.0–39.0)
Heart rate, beats per min 85 140 (125–150)
White blood cell count, 109/l 98 12.0 (9.0–16.8)
Platelet count, 109/l 69 265.0 (190.0–444.0)
Haematocrit, % 67 47.0 (43.5–52.5)
IQR, interquartile range.
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response to tetanus vaccination.7
In neonatal tetanus, entry of tetanus toxin into the central
nervous system results in muscle spasms, initially interfering with
the ability to suck and feed, but later involving the chest muscles,
impeding respiration. Without medical treatment mortality rates
are very high (some reports are of 99% fatality).8,9 As tetanus
evolves over days in a characteristic manner, the recognition of
prognostic features on presentation may enable timely interven-
tion and triage.
Generally, rapid disease progression in tetanus is associated
with a worse outcome.8,10 Most studies have been performed in
adults, but several case series in neonates have found similar
indicators of prognosis.11–13 Lambo and Anokye recently
performed a meta-analysis and included data from 4535 neonates
to ascertain which features are most relevant in neonates. They
concluded that low birth weight and age at onset were the most
important factors in determining the outcome.14 The authors
criticized the studies included in the analysis for limited
prospective data and lack of control for gestational age. They
noted that only one out of the 16 studies included all of the
prognostic factors selected for the analysis and they were unable
to ﬁnd consistent reporting on delay in admission to hospital or
duration of hospital stay to include these in their analysis, as
originally intended. In some studies, current standard therapies
such as tetanus anti-toxin were not necessarily used. Many of the
studies included were conducted over 40 years ago, and even
relatively recent studies used patient data from preceding
decades. (The study by Patel and Mehta published in 1999 and
including 1490 neonates, used data from the period 1954–68.8) In
total, 3648 out of 4535 cases were admitted before 1996. Most of
the studies were therefore either conducted in settings without
facilities for mechanical ventilation or were performed before
such facilities were readily available.
The availability of mechanical ventilation allows respiratory
muscle spasm to be controlled and prevents respiratory failure –
the major cause of death in tetanus. Recent improvements in
critical care capacity in many low- and middle-income countries
has meant improved supportive therapy is now available for a
larger number of cases of neonatal tetanus. However, it is not
known whether this has affected the reliability of factors identiﬁed
to be associated with a worse prognosis in settings without these
facilities.
In all settings the ability to rapidly identify those neonates at
highest risk of a poor outcome may be especially important to
target medical and nursing care appropriately. Knowledge of
prognostic factors is also important to determine the efﬁcacy of
interventions over time and between locations. Baseline
comparison of prognostic factors allows more accurate deter-
mination of likely disease progression before any treatment is
begun. As some newer interventions in tetanus have been
reported to reduce disease progression itself, this is especially
important.15–17
In adult patients with tetanus, the efﬁcacy of some interven-
tions has been disputed due to potential differences in the severity
of disease in the populations studied and the lack of consensus
regarding how to quantify this.18 Some publications have used
only overall mortality rates as a marker of disease severity.19 In
neonatal tetanus, with wide variations in management and
mortality rates ranging from 0 to 70% in different centres,
improved indicators of disease severity are needed.13,20–22
In this study, we analyzed data from patients admitted with
neonatal tetanus to our intensive care units. We examined
multiple prognostic factors associated with outcome over a
period of time during which improvements in critical care
facilities were made.2. Methods
All study patients were admitted to the Hospital for Tropical
Diseases, Ho Chi Minh City, Vietnam between 1997 and 2012. The
Hospital for Tropical Diseases is a tertiary referral hospital for
infectious diseases and admits patients from the whole of southern
Vietnam (population around 45 million). The reorganization of
medical services in 2006 resulted in patients with neonatal tetanus
being admitted to a specialist paediatric intensive care unit rather
than the dedicated tetanus intensive care unit that had served all
age groups and has been described previously.23 Facilities for the
intensive care management of neonates available at the Hospital
for Tropical Diseases include mechanical ventilation and invasive
blood pressure monitoring. Over the course of the study, these
facilities were gradually incorporated into standard neonatal
tetanus management. Mechanical ventilation was ﬁrst used in the
management of neonatal tetanus in 2000. Invasive blood pressure
monitoring was introduced in 2008 following the transfer of care
to the specialist paediatric intensive care unit.
Two datasets were used for the analysis. For most analyses, data
from both phases were combined. The ﬁrst was a prospective
collection of data from 87 consecutive neonatal tetanus cases
admitted between 1997 and 2003 to the Tetanus Unit at the
Hospital for Tropical Diseases as part of an ongoing tetanus
surveillance programme.23,24 The second phase of the study
consisted of case record analysis of 20 consecutive patients with
neonatal tetanus admitted to the paediatric intensive care unit at
the same hospital from January 2010 to December 2012.25
Clinical and demographic data were collected (Table 1). The
incubation period was deﬁned as the time between birth and ﬁrst
symptom, assuming umbilical portal of entry. The period of onset
was deﬁned as the time between ﬁrst symptom and ﬁrst
generalized muscle spasm. Cases of ‘discharge to die at home’ or
‘discharge against medical advice’ were recorded as deaths, as
these were felt certain to result in this outcome due to the severity
of the disease. In phase 1 of the study, the results of routine
neurological examinations performed on discharge were recorded,
including screening for gross deﬁcits and general development.
Studies were approved by the scientiﬁc ethics committee of the
Hospital for Tropical Diseases.
All data were entered into a specially designed database and
extracted for analysis. Frequencies (%) and the median (with
interquartile range, IQR) were used to describe data. Age and
weight on admission were compared between phases of the study
using the Wilcoxon rank sum test.
As mortality rates declined during the study period, we used a
combined poor outcome endpoint of either death or staying in
hospital for more than 40 days as a more sensitive means of
detecting a poor outcome in a setting of low mortality. The cut-off
of 40 days was based on the 75th percentile of the length of hospital
stay in patients who survived. Logistic regression was used for
both univariate and multivariable analyses. Predeﬁned covariates
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heart rate, white blood cell count, and platelet count), and onset-
related variables (time from ﬁrst symptom to admission, incuba-
tion period, and the period of onset) were selected based on
previous studies and clinical knowledge.6,14,15 Temperature, heart
rate, and haematocrit on admission were not available for patients
in phase 2 of the study. In the multivariable analyses, we excluded
incubation period, as it was strongly related to age on admission
but less reliable. We also included study period as a categorical
variable, with three levels (1997–1999, 2000–2003, 2010–2012),
in all univariate and multivariable analyses to adjust for changes in
outcomes over time, because signiﬁcant changes in management
were made during these periods. As there was strong evidence for a
non-linear effect of the time from ﬁrst symptoms to admission on
outcomes, we modelled separate linear effects for durations <6
days and 6 days, respectively. Univariate analyses were based on
a complete-case analysis, excluding subjects with missing
information for that variable. Multivariable analyses were based
on multiple imputation of missing data. Effects of covariates on
outcomes were summarized as the odds ratio (OR) with
corresponding 95% conﬁdence interval (95% CI). The following
software was used in the analysis: IBM SPSS Statistics for Windows
version 19.0 (IBM Corp., Armonk, NY, USA), R version 3.0.2 (R
Foundation for Statistical Computing, Vienna, Austria), and the
companion R package MICE version 2.21 for multiple imputation.26
3. Results
A total of 107 cases were included in the study: 87 in phase 1 and
20 in phase 2. Fifty-nine percent of patients were male. All except
two patients were reported to be delivered at full term, with two
patients having preterm delivery dates of 8 months and 8.5 months.
Admission characteristics are shown in Table 1. The median age on
admission was 8 days (IQR 6–11 days) and median weight on
admission was 2.8 kg (IQR 2.5–3 kg). These variables did not differ
between the two study groups (p-values 0.847 and 0.353, respective-
ly). The median time from ﬁrst symptom to admission was 3 days (IQR
2–3.25 days). The median incubation period was 6 days (IQR 5–8
days), and the median period of onset was 24 h (IQR 24–24 h).
The overall mortality rate in the study was 40.2% (43/107). This
changed signiﬁcantly over time, falling from 58.7% (27/46) in years
1997–1999 to 31.7% (13/41) in 2000–2003, and ﬁnally to 15.0% (3/
20) in 2010–2012 (likelihood ratio test, p < 0.001).Table 2
Univariate effect of selected variables on mortality or length of hospital stay >40 days
Mortality or LOS >40 
Variable n OR 95% CI 
Age (+1 day) 107 0.65 (0.52–0
Weight (+1 kg) 103 0.09 (0.02–0
First symptom to admission 104 
+1 day, if <6 daysa 0.49 (0.31–0
+1 day, if 6 daysb 1.60 (0.77–3
Incubation period (+1 day) 105 0.77 (0.66–0
Period of onset (+1 h) 102 0.93 (0.89–0
Temperature (+1 8C) 84 1.28 (0.82–2
Heart rate (+10 beats per min) 85 1.37 (1.01–1
White blood cell count (+1000/mm3) 98 1.10 (1.01–1
Platelet count (+10 000/mm3) 69 1.00 (0.97–1
Haematocrit (+1%) 67 1.04 (0.97–1
LOS, length of hospital stay; OR, odds ratio; CI, conﬁdence interval. All analyses were adju
change in that variable to produce the described OR. As an example, the OR of 0.65 for age
the combined outcome of mortality or stay in the hospital for >40 days by 35%.
a The corresponding OR indicates the predicted change in the odds of the outcome for
durations is <6 days.
b The corresponding OR indicates the predicted change in the odds of the outcome for e
days.In contrast there was no clear evidence of change in the
combined outcome measure of hospital stay >40 days or death,
which was not signiﬁcantly different between study periods: 63.0%
(29/46), 51.2% (21/41), and 75% (15/20) for the same time intervals
(likelihood ratio test, p = 0.179).
The analysis of admission factors in relation to the combined
outcome measure and mortality is shown in Table 2. Younger age,
reduced weight, shorter incubation period and period of onset, and
increased white blood cell count on admission were all associated
with increased mortality. In addition, a raised heart rate on
admission was associated with the combined endpoint of death or
prolonged hospital stay. The time from ﬁrst symptoms to
admission showed a pronounced non-linear effect on both
outcomes (p-values for quadratic trend <0.01 for both outcomes)
and therefore its effect was modelled as separate linear effects for
durations <6 days and 6 days, respectively. In the univariate
analysis, time from ﬁrst symptom to admission was signiﬁcantly
associated with mortality (p < 0.001) and showed a U-shaped
association: the risk of death decreased up to a period of 6 days, but
increased again when the period was longer than 6 days. The risk of
the combined endpoint also decreased signiﬁcantly up to a period
of 6 days (p < 0.001), but did not signiﬁcantly change afterwards.
In the multiple logistic regression analysis of selected variables,
shown in Table 3, weight and age were signiﬁcantly associated with
the composite endpoint: the OR for each kilogram increase in weight
was 0.11 (95% CI 0.01–0.75) and the OR for each day increase in age
was 0.73 (95% CI 0.56–0.95). Factors associated with mortality alone
additionally included an increase in white blood cell count (OR for
each 1000 cells increase 1.17, 95% CI 1.02–1.35), shorter period of
onset (OR for each hour increase 0.94, 95% CI 0.88–0.99), and
increased time from ﬁrst symptom to admission when this was 6
days (OR for each day increase 3.77, 95% CI 1.14–12.51).
Twenty-six surviving patients in phase 1 of the study had a
discharge assessment recorded. Overall 25/26 (96%) were consid-
ered to be developmentally normal for age at discharge, however
8/35 (23%) had residual muscle stiffness on discharge. Two
patients returned for follow-up at 6 months and were examined
by an experienced paediatrician. Both were judged developmen-
tally normal for age.
4. Discussion
There are few reports of the outcome of neonatal tetanus in
centres with facilities for mechanical ventilation and intensive care, and mortality only
days Mortality
p-Value OR 95% CI p-Value
.77) <0.001 0.68 (0.53–0.81) <0.001
.29) <0.001 0.09 (0.02–0.32) <0.001
<0.001
.72) <0.001 0.44 (0.26–0.69) <0.001
.80) 0.212 4.29 (1.81–12.93) <0.001
.88) <0.001 0.79 (0.66–0.91) <0.001
.96) <0.001 0.94 (0.90–0.97) <0.001
.03) 0.285 1.14 (0.73–1.81) 0.561
.89) 0.040 1.1 (0.82–1.48) 0.526
.21) 0.025 1.09 (1.01–1.19) 0.024
.04) 0.864 1.01 (0.98–1.05) 0.568
.10) 0.262 1.04 (0.97–1.11) 0.249
sted for time-period. Numbers in brackets after each variable indicate the required
 indicates that a 1-day increase in age results in a predicted reduction of the odds of
 each increase in the time since ﬁrst symptom to admission by +1 day as long as the
ach increase in the time since ﬁrst symptom to admission by +1 day for durations 6
Table 3
Multivariable effect of selected variables on mortality or length of hospital stay >40 days, and mortality only (n = 107)
Mortality or LOS >40 days Mortality
Variable OR 95% CI p-Value OR 95% CI p-Value
Age (+1 day) 0.73 (0.56–0.95) 0.021 0.69 (0.48–0.99) 0.042
Weight (+1 kg) 0.11 (0.01–0.75) 0.025 0.06 (0.01–0.54) 0.011
First symptom to admission
+1 day, if <6 daysa 0.77 (0.38–1.55) 0.466 0.72 (0.30–1.69) 0.446
+1 day, if 6 daysb 1.13 (0.39–3.28) 0.817 3.77 (1.14–12.51) 0.029
Period of onset (+1 h) 0.94 (0.87–1.00) 0.067 0.94 (0.88–0.99) 0.046
Temperature (+1 8C) 1.45 (0.65–3.26) 0.364 1.40 (0.60–3.25) 0.431
Heart rate (+10 beats per min) 1.02 (0.97–1.08) 0.379 0.98 (0.92–1.03) 0.402
White blood cell count (+1000/mm3) 1.11 (0.96–1.27) 0.147 1.17 (1.02–1.35) 0.026
Platelet count (+10 000/mm3) 1.00 (0.99–1.00) 0.724 1.00 (0.99–1.01) 0.968
Haematocrit (+1%) 0.96 (0.85–1.07) 0.442 0.97 (0.84–1.11) 0.664
Study period
1997–1999 1.00 1.00
2000–2003 0.74 (0.13–4.06) 0.729 0.06 (0.01–0.41) 0.004
2010–2012 2.01 (0.19–20.58) 0.556 0.01 (0.001–0.17) 0.002
LOS, length of hospital stay; OR, odds ratio; CI, conﬁdence interval. All missing data were imputed using multiple imputation. Numbers in brackets after each variable indicate
the required change in that variable to produce the described OR. As an example, the OR of 0.73 for age indicates that a 1-day increase in age results in a predicted reduction of
the odds of the combined outcome of mortality or stay in the hospital for >40 days by 27%.
a The corresponding OR indicates the predicted change in the odds of the outcome for each increase in the time since ﬁrst symptom to admission by +1 day as long as the
durations is <6 days.
b The corresponding OR indicates the predicted change in the odds of the outcome for each increase in the time since ﬁrst symptom to admission by +1 day for durations
6 days.
P.K. Lam et al. / International Journal of Infectious Diseases 33 (2015) e7–e11e10management. Jeena et al. reported outcomes and epidemiological
factors in 27 cases of neonatal tetanus treated in a paediatric
intensive care unit in South Africa in 1993, but did not analyze
prognostic factors.27 We have previously shown in adults patients
with tetanus that the prognosis is dependent on multiple
variables.10 The recent meta-analysis by Lambo et al., which
included 16 studies, examined only three variables: birth weight,
age at onset, and age at presentation. They were unable to assess
length of hospital stay and delay in hospitalization due to a lack of
these data, but results showed that both age at presentation and
birth weight were important predictors of mortality.12 The
studies included in the meta-analysis were performed in Asia and
Africa, spanning ﬁve decades, and included wide variations in
management.
Despite the broader group of prognostic variables we examined,
weight and age remained signiﬁcant predictors of outcome. White
blood cell count and heart rate were also associated with poor
outcome in our series. This is consistent with previous ﬁndings in
adults.8,10 However other factors also signiﬁcant in adults, such as
temperature on admission, were not found to be important
markers of neonatal outcome. This may be due to our sample size
or may reﬂect their relative unimportance in this age-group.
A delay in admission to hospital was associated with a worse
outcome. For periods of time from ﬁrst symptom to admission of
6 days, increasing time period was signiﬁcantly associated with
a poor outcome in the univariate analysis for both endpoints
and remained signiﬁcant in the multivariate model for mortality.
Increased time from onset of symptoms to treatment may allow
for increased toxin load or the development of secondary
complications such as dehydration, sepsis, or aspiration pneumo-
nia. The univariate analysis, however, showed that for shorter
periods of time (<6 days) there was a reduced risk of a poor
outcome with increasing time. This is likely to reﬂect the effect of
rapid progression of severe disease, and in the multivariate model
the effect was no longer signiﬁcant when other variables such as
age at presentation were included.
As the mortality rate declined signiﬁcantly during the study
period, we chose a combined endpoint of death or prolonged
hospital stay to try and increase the sensitivity of our study. The
combined endpoint measure did not show evidence of signiﬁcant
change over time and was associated with the same prognosticvariables as mortality alone. Thus we believe this measure is an
acceptable option when mortality rates are low and could be
used to assess the efﬁcacy of new interventions in settings such
as ours. Indeed as the mortality rate changed signiﬁcantly over
time, the prognostic factors established as predictors of
mortality may be inﬂuenced by the higher number of deaths
in the earlier years of the study. Thus in choosing the most
relevant prognostic factors to use clinically in future, those
signiﬁcant for both endpoints are perhaps the most important,
i.e., age and weight.
We also note that a signiﬁcant number of patients have hospital
stays over 40 days. Previously some authors have deﬁned neonatal
tetanus mortality as ‘death within 28 days’.12 Three patients in
phase 1 of this study, although no patients in phase 2, died after
28 days. Thus in centres where early deaths due to respiratory
failure are avoided, such a deﬁnition is likely to underestimate true
mortality.
In conclusion, the numbers of cases of neonatal tetanus admitted
to our hospital over the last 15 years have fallen signiﬁcantly and the
outcome from the disease has improved. Prognostic factors
previously identiﬁed in different settings, notably those with fewer
resources, were still found to be associated with worse outcomes. In
addition we have shown that a delay in admission to hospital and
other factors associated with a worse prognosis in adults are also
important in neonates in this setting. Survivors of neonatal tetanus
require long periods of hospitalization and intensive care unit care,
but little is known about long-term outcomes. Future research
should be aimed at identifying cost-effective treatments able to
reduce the duration of hospital stay as well as mortality, and at
assessing long-term outcomes.
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